![Dr John Ford](https://enterprisetherapeutics.com/wp-content/uploads/2018/07/John-Ford.jpg)
Dr John Ford
John has more than 20 years’ experience building innovative and successful biotechnology companies. He co-founded Xention (CSO), Ario Pharma (CEO) and Metrion Biosciences (co-owner). More...
![Prof Martin Gosling](https://enterprisetherapeutics.com/wp-content/uploads/2018/07/Martin-Gosling.jpg)
Prof Martin Gosling
Prof Martin Gosling has spent his research career exploiting the therapeutic potential of ion channels in both industrial and academic settings. More...
![Dr David Morris MD](https://enterprisetherapeutics.com/wp-content/uploads/2018/09/David-Morris.jpg)
Dr David Morris MD
David is a Venture Partner at NVF in San Francisco, CA, USA. Prior to joining NVF, he held multiple leadership roles in the Novartis Pharmaceuticals development organization More...
![Dr Henry Danahay](https://enterprisetherapeutics.com/wp-content/uploads/2018/07/Danahay.jpg)
Dr Henry Danahay
Dr Henry Danahay gained a BPharm and PhD from the Welsh School of Pharmacy before joining the Novartis Respiratory Diseases Group. More...
![Dr Stephen Collingwood](https://enterprisetherapeutics.com/wp-content/uploads/2018/07/Stephen-Collingwood.jpg)
Dr Stephen Collingwood
Dr Steve Collingwood obtained his first degree in chemistry from the University of Durham and his PhD in organic chemistry from the University of Newcastle. More...
![Dr Phil Boyd](https://enterprisetherapeutics.com/wp-content/uploads/2018/07/Phil-Boyd.jpg)
Dr Phil Boyd
Dr Phil Boyd was CFO of Syntaxin Ltd from 2007 through to the acquisition by Ipsen in July 2013, and CFO of Tiziana Lifesciences plc (AIM: TILS) from 2014 to 2015. More...
![Paul Russell](https://enterprisetherapeutics.com/wp-content/uploads/2018/07/Paul-Russell.jpg)
Paul Russell
Paul has more than 20 years’ experience in the pharma and biotech industry. More...